Pharmathen announced today the acquisition of CBL Patras, a vertically integrated, high-tech peptide manufacturing company approved by the US Food and Drug Administration (FDA). The acquisition of CBL confirms Pharmathen's commitment to innovation and its dedication to long-term growth, further strengthening its position in the global therapeutic peptides market, which is currently valued at €38 billion and is expected to reach €100 billion by 2033.

Danish Teracloud is creating a research centre in Athens. Teracloud was founded in 2015 and employs 400 people worldwide. It has a presence in Malmö, Sweden; Stuttgart, Germany; Yerevan, Armenia; Perth, Australia; and Boston, USA, developing complex technology applications that enable businesses to digitise their processes and become more competitive.